enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

(Neutral)

Rhea-AI Summary

enVVeno Medical (NASDAQ:NVNO) will present in the Webull Corporate Connect Webinar Series, held virtually June 24‑25, 2026. CEO Rob Berman will speak on June 24, 2026 from 2:00–2:20 PM ET, covering the company’s deep venous disease focus, recent FDA IDE approval for the enVVe® System, and plans for a first U.S. pivotal trial of a non-surgical replacement venous valve.

News Market Reaction – NVNO

+5.00%

+5.00% Session close to close

In the Jun 22 session, NVNO gained 5.00%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.0% in the session following this news. A strong positive reaction aligns with rec...

Analysis

The stock moved +5.0% in the session following this news. A strong positive reaction aligns with recent IDE approval milestones and prior constructive earnings updates, but elevated short positioning and past selloffs on good news could still cap follow-through if future trial or funding updates disappoint.

Key Figures

Webinar date range: June 24–25, 2026 Webinar time: 2:00 PM ET Presentation window: 2:00–2:20 PM ET

3 metrics

Webinar date range June 24–25, 2026 Webull Corporate Connect Webinar Series schedule

Webinar time 2:00 PM ET Start time of NVNO live webcast on June 24, 2026

Presentation window 2:00–2:20 PM ET Scheduled duration of CEO presentation on June 24, 2026

Historical Context

5 past events · Latest: Jun 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 02	Investor webinar	Positive	+0.7%	CEO participation in Virtual Investor event discussing FDA IDE approval and Q&A.
May 12	Regulatory discussion	Positive	-5.7%	CEO segment explaining first-ever FDA IDE approval for non-surgical venous valve study.
May 07	Earnings update	Positive	+1.5%	Q1 2026 results and cash runway update tied to enVVe pivotal study plans.
Apr 29	IDE approval	Positive	-10.8%	First-ever FDA IDE approval for U.S. pivotal study of non-surgical venous valve.
Mar 27	Full-year earnings	Positive	+0.8%	2025 results and advancement of enVVe System toward a pivotal trial in 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

NVNO often shows negative reactions to major positive regulatory milestones, while routine updates and earnings tend to see small positive moves.

Key Terms

fda ide approval, deep venous insufficiency, pivotal trial, non-surgical replacement venous valve

4 terms

fda ide approval regulatory

"review the recent FDA IDE approval for the Company's enVVe® System, and outline"

An FDA Investigational Device Exemption (IDE) approval is the U.S. regulator’s authorization to test a medical device in human clinical trials. For investors, it’s like a formal permit to move from lab development to real-world testing: it lets a company collect essential safety and effectiveness data, reduces regulatory uncertainty, and can be a clear milestone that unlocks funding, partnerships, or valuation inflection points.

deep venous insufficiency medical

"unmet need for patients suffering from severe Deep Venous Insufficiency (DVI), review"

Deep venous insufficiency is a condition where the one-way valves in the deep veins of the legs fail, letting blood pool or flow backward instead of returning efficiently to the heart — imagine valves in a pipe that no longer close properly. For investors, it matters because it drives demand for treatments, diagnostic tests and medical devices, influences healthcare spending and reimbursement trends, and can affect the commercial prospects and regulatory risk for companies developing related therapies.

pivotal trial clinical

"plans for advancing the first-ever U.S. pivotal trial of a non-surgical"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

non-surgical replacement venous valve medical

"U.S. pivotal trial of a non-surgical replacement venous valve."

A non-surgical replacement venous valve is a medical device placed inside a vein through a small incision or catheter to restore the one-way flow that damaged vein valves normally provide, avoiding open surgery. Think of it as a plug-in valve that corrects backflow like fixing a leaky one-way gate; for investors, it matters because successful devices can reduce hospital time, lower procedure costs, expand patient access, and drive revenue through device sales, procedures, and related follow-up care.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/22/2026 - 09:00 AM

- Live webcast on Wednesday, June 24^th at 2:00 PM ET

- Access the event here

IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company setting new standards of care for the treatment of deep venous disease, today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026.

As part of the discussion, the Company's CEO, Rob Berman, will provide an overview of enVVeno Medical's mission to transform the treatment of deep venous disease, discuss the significant unmet need for patients suffering from severe Deep Venous Insufficiency (DVI), review the recent FDA IDE approval for the Company's enVVe^® System, and outline plans for advancing the first-ever U.S. pivotal trial of a non-surgical replacement venous valve.

Details for the presentation are as follows:

Date and Time: Wednesday, June 24, 2026 at 2:00 - 2:20 PM ET
Presenter: Robert Berman, enVVeno Medical's Chief Executive Officer
Registration Link: HERE

About Webull Financial
Webull Corporation owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 16 markets across North America, Asia Pacific, Europe, Africa, and Latin America. Webull serves more than 27 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull's trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at www.webullcorp.com.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company is currently developing the enVVe system, which includes a first-in-class non-surgical replacement venous valve being developed for the treatment of severe Deep Venous Insufficiency (DVI). The enVVe valve is designed to act as one-way valve, to help assist in propelling blood up the leg, and back to the heart and lungs. As a transcatheter delivered device, the enVVe procedure will be performed under light sedation and should not require an over-night hospital stay.

INVESTOR CONTACT:
JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

FAQ

When is enVVeno Medical (NASDAQ:NVNO) presenting in the Webull Corporate Connect Webinar Series?

enVVeno Medical will present on Wednesday, June 24, 2026, from 2:00 to 2:20 PM ET. According to enVVeno Medical, the session is part of the virtual Webull Corporate Connect Webinar Series running June 24–25, 2026, and will feature the company’s CEO.

Who will present for enVVeno Medical (NASDAQ:NVNO) at the June 24, 2026 Webull webinar?

enVVeno Medical’s Chief Executive Officer, Robert (Rob) Berman, will lead the June 24, 2026 presentation. According to enVVeno Medical, he will outline the company’s mission, discuss deep venous disease needs, review enVVe® System FDA IDE approval, and describe pivotal trial plans.

What topics will enVVeno Medical (NASDAQ:NVNO) cover during its Webull Corporate Connect webinar?

The webinar will cover enVVeno Medical’s mission, deep venous disease needs, and its enVVe® System. According to enVVeno Medical, Rob Berman will also discuss the recent FDA IDE approval and plans to advance the first U.S. pivotal trial of a non-surgical replacement venous valve.

What is the enVVe System that enVVeno Medical (NASDAQ:NVNO) will discuss on June 24, 2026?

The enVVe® System is a non-surgical replacement venous valve platform for deep venous disease. According to enVVeno Medical, it recently received FDA IDE approval, and the company plans to advance the first-ever U.S. pivotal trial of such a non-surgical replacement venous valve.

How can investors register for the enVVeno Medical (NASDAQ:NVNO) Webull Corporate Connect webinar?

Investors can register using the designated online registration link provided for the event. According to enVVeno Medical, access is available through the event’s “Access the event here” and “Registration Link: HERE” references associated with the June 24, 2026 webinar.